by CheckRare Staff | Jan 20, 2022
Ajai Chari, MD from the Mount Sinai School of Medicine discusses the TRiMM-2 study of teclistamab and talquetamab in combination with daratumumab in the treatment of relapsed/refractory multiple myeloma. Results from this study were recently presented in two...
by Peter Ciszewski | Jan 19, 2022
Jacob Laubach, MD at the Dana-Farber Cancer Institute discusses updated safety and efficacy data from the phase 2 GRIFFIN trial assessing daratumumab plus lenalidomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma patients. The data were...
by Peter Ciszewski | Jan 18, 2022
Brendan Delaney, MBA, Chief Operating Officer of Aadi Bioscience, discusses albumin-bound sirolimus (Fyarro), the recently-approved treatment for malignant perivascular epithelioid cell tumor (PEComa). PEComa is an ultra-rare family of sarcomas. Most PEComa...
by CheckRare Staff | Jan 17, 2022
Bradley Galer, MD, Executive Vice President and Chief Medical Officer, Zogenix, discusses MT1621, an investigational treatment for thymidine kinase 2 deficiency (TK2d). TK2d is an ultra-rare genetic mitochondrial disease characterized by progressive myopathy,...
by James Radke, PhD | Jan 14, 2022
Jerry Vockley, MD, PhD, Head of the Division of Medical Genetics at UPMC Children’s Hospital of Pittsburgh, gives an overview of the treatment landscape for phenylketonuria (PKU), going further into detail about the mechanism of action of SYNB1618, an oral drug...
